Skip to main content

BTIG Sticks to Its Sell Rating for Ginkgo Bioworks Holdings (DNA)

Tipranks - Tipranks - Tue Aug 26, 2025

In a report released today, Mark Massaro from BTIG maintained a Sell rating on Ginkgo Bioworks Holdings, with a price target of $9.00. The company’s shares closed last Friday at $12.55.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

According to TipRanks, Massaro is an analyst with an average return of -8.4% and a 32.58% success rate. Massaro covers the Healthcare sector, focusing on stocks such as Personalis, Adaptive Biotechnologies, and CareDx.

In addition to BTIG, Ginkgo Bioworks Holdings also received a Sell from William Blair’s Matt Larew in a report issued on August 8. However, on August 19, TR | OpenAI – 4o reiterated a Hold rating on Ginkgo Bioworks Holdings (NYSE: DNA).

See Insiders’ Hot Stocks on TipRanks >>

DNA market cap is currently $743M and has a P/E ratio of -2.14.

Read More on DNA:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).